2009
DOI: 10.1016/j.yebeh.2009.04.006
|View full text |Cite
|
Sign up to set email alerts
|

Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: Clinical and outcome implications

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

6
33
0
2

Year Published

2011
2011
2016
2016

Publication Types

Select...
6
3
1

Relationship

0
10

Authors

Journals

citations
Cited by 48 publications
(41 citation statements)
references
References 11 publications
6
33
0
2
Order By: Relevance
“…For example, renal clearance increases substantially during pregnancy, and small studies demonstrate that LEV levels decrease by 40 % to 62 % during the second and third trimesters [36][37][38][39]. A more detailed analysis of 12 pregnancies demonstrated an even greater change in clearance of LEV from nonpregnant baseline to the third trimester, with a mean ± SD increase from 124.7 ± 57.9 l/day to 427.3 ± 211.3 (p < 0.0001), an increase of 242 % [37].…”
Section: Role Of Therapeutic Drug Monitoring In Maintaining Seizure Cmentioning
confidence: 99%
“…For example, renal clearance increases substantially during pregnancy, and small studies demonstrate that LEV levels decrease by 40 % to 62 % during the second and third trimesters [36][37][38][39]. A more detailed analysis of 12 pregnancies demonstrated an even greater change in clearance of LEV from nonpregnant baseline to the third trimester, with a mean ± SD increase from 124.7 ± 57.9 l/day to 427.3 ± 211.3 (p < 0.0001), an increase of 242 % [37].…”
Section: Role Of Therapeutic Drug Monitoring In Maintaining Seizure Cmentioning
confidence: 99%
“…Hunt és mtsai vizsgálatában 2,7%-os a fejlődési rendellenességek előfordulási gyakorisága az általuk vizsgált 117, LEV-kezelésben részesülő édesanyánál [33]. López-Fraile és mtsai által követett epilepsziás anyák újszülött-jeinél nem fordult elő fejlődési rendellenesség, LEV-vel fenntartható volt a kívánt rohammentesség terhesség és szülés alatt [34]. Vajda és mtsai 2014-ben megjelent tanulmányában a legújabb generációs szerek alacsonyabb teratogén potenciáljáról számolnak be a valproáttal, illetve carbamazepinnel összehasonlítva [35].…”
Section: Levetiracetamunclassified
“…intentional reduction or discontinuation of medication to protect the child), sleep disturbances, and higher clearance (Fotopoulou 2009, López-Fraile 2009, Westin 2009). intentional reduction or discontinuation of medication to protect the child), sleep disturbances, and higher clearance (Fotopoulou 2009, López-Fraile 2009, Westin 2009).…”
Section: Frequency Of Seizures In Pregnancymentioning
confidence: 99%